Modulation of Insulin Sensitivity by Betaine Upregulation of FGF21



Status:Completed
Conditions:Endocrine
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:21 - 70
Updated:5/5/2014
Start Date:March 2014
End Date:July 2014
Contact:Tondra Blevins
Email:tondra_blevins@unc.edu
Phone:704-250-5035

Use our guide to learn which trials are right for you!

People with poor insulin sensitivity do not respond normally to elevations in blood sugar.
This may increase their risk of developing diabetes in the future. The purpose of this
research study is to determine if the nutrient betaine, found in beets, spinach and wheat
products, can enhance the production of fetal growth factor 21 (FGF21), a molecule that is
believed to promote insulin sensitivity.

AIM: To determine if betaine is a modulator of FGF21 in humans. Low plasma betaine is
associated with an increased risk of metabolic syndrome, but the mechanisms modulating this
correlation are poorly delineated. Betaine bioavailability in humans is determined by
dietary intake and genetic polymorphisms that influence betaine metabolism. Therefore,
moderating betaine levels could be particularly beneficial for some individuals. FGF21 is
elevated in response to insulin insensitivity and is under active investigation as a
therapeutic modality. The mechanisms of action of FGF21 and betaine on insulin sensitivity
in humans are incompletely understood. This study tests the hypothesis that betaine induces
FGF21 secretion and insulin sensitizing actions in humans by measuring plasma FGF21,
betaine, choline (betaine precursor), glucose, insulin and adiponectin in response to
betaine supplementation over a 24 hour time course in 20 healthy, lean individuals. This
pilot nutrition intervention will provide key preliminary evidence for understanding whether
and how betaine exerts metabolic benefit in humans and will inform a future study to
investigate the novel betaine-FGF21-insulin sensitivity axis in a larger cohort.

Inclusion Criteria:

- Healthy

- Able/willing to consume study meals

- Non-smoker

- BMI in normal range (18-24.9)

Exclusion Criteria:

- Use of chronic medications

- Abnormal physical examination or chronic illness

- Use of drugs or medications known to alter choline/betaine metabolism

- Consumption of more than 2 oz of alcohol/day or 24 oz wine/day

- Use of choline/betaine-containing dietary supplements during the previous 3 months

- Diagnosed with Cystathionine Beta-Synthase (CBS) Deficiency

- Pregnant or breastfeeding

- Known hypersensitivity to betaine

- Current substance abuse or addiction
We found this trial at
1
site
Kannapolis, North Carolina 28081
?
mi
from
Kannapolis, NC
Click here to add this to my saved trials